Research
Icariin (Horny Goat Weed)
12 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Efficacy and mechanisms of Icariin in the treatment of Alzheimer's disease: a systematic review and meta-analysis of a preclinical study.
Systematic review and meta-analysis of 31 preclinical studies on icariin's effects in animal models of Alzheimer's disease. Icariin significantly improved cognitive dysfunction through mechanisms like resistance to neurotoxic substances, inhibition of oxidative stress, and promotion of nerve regeneration. 68 mg/kg was identified as the most effective dose for improving cognition.
Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post-menopausal women.
RCT of 58 postmenopausal women examining the safety and pharmacokinetics of Epimedium prenylflavonoids. The study found that EP prenylflavonoids were safe and associated with higher levels of bone specific alkaline phosphatase, suggesting potential therapeutic value for post-menopausal osteoporosis.
The antiosteoporosis effect of icariin in ovariectomized rats: a systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the efficacy of icariin against osteoporosis in ovariectomized rats. Results showed that icariin-treated rats had significantly higher bone mineral density and improved bone histomorphometric parameters compared to controls, suggesting a substantial antiosteoporosis effect.
Bone mass improved effect of icariin for postmenopausal osteoporosis in ovariectomy-induced rats: a meta-analysis and systematic review.
Meta-analysis and systematic review of icariin's effect on bone mass in ovariectomy-induced rat models of postmenopausal osteoporosis. Icariin significantly improved bone mass as assessed by bone mineral density compared to control, with no significant difference compared to estrogen.
A systematic review of the efficacy and pharmacological profile of Herba Epimedii in osteoporosis therapy.
Systematic review assessing the efficacy and pharmacological profiles of Herba Epimedii in osteoporosis therapy. The review highlights the bone-strengthening activity of Herba Epimedii and its active compounds, such as total flavonoids and icariin, and summarizes studies on their osteoprotective effects.
Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
A 24-month randomized double-blind placebo-controlled trial evaluated the effect of Epimedium-derived phytoestrogen flavonoids on bone mineral density (BMD) in late postmenopausal women. The EPF treatment group maintained BMD, while the placebo group showed a decrease. EPF intervention significantly decreased levels of deoxypyridinoline, a bone turnover marker, without affecting serum estradiol or endometrial thickness.
Pharmacokinetics of Prenylflavonoids following Oral Ingestion of Standardized Epimedium Extract in Humans.
This study investigated the pharmacokinetics and safety of prenylflavonoids from a standardized Epimedium extract in 30 healthy male subjects. The extract was well tolerated, and the main metabolites detected were icariside II and desmethylicaritin. The study suggests potential anti-osteoporotic effects, warranting further research.
Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review
This review discusses strategies to improve the bioavailability of icariin and its derivates, icariside II and icaritin, which have potential applications in preventing cancer, cardiovascular disease, osteoporosis, Alzheimer's disease, and treating erectile dysfunction. The paper gathers the latest knowledge on pharmaceutical technologies, structural transformations, and absorption enhancers to enhance the efficacy of these flavonoids.
Effect of Icariin on apoptosis and expression of Fas, Fas ligand, B cell lymphoma, and Bcl-2-associated X protein in CD4+ T lymphocytes from patients with ankylosing spondylitis.
The study investigated the effects of icariin on apoptosis and expression of apoptosis-related proteins in CD4+ T lymphocytes from patients with ankylosing spondylitis. Icariin increased the expression of Fas and activity of caspase 8 and caspase 3, while decreasing Bcl-2 expression, indicating a proapoptotic effect that was dose-dependent.
An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder.
Open-label pilot study of icariin in 10 participants with bipolar disorder and alcohol abuse or dependence. Significant decreases were observed in depression and anxiety scores, as well as in heavy drinking days and standard drinks. Icariin was well tolerated with no withdrawals due to side-effects.
Roles of the antioxidant properties of icariin and its phosphorylated derivative in the protection against duck virus hepatitis.
The study investigated the antioxidative and hepatoprotective effects of icariin and its phosphorylated derivative against duck viral hepatitis. Administration of icariin or p-icariin improved survival rates and attenuated liver injury and oxidative stress in ducklings, with p-icariin showing better outcomes.
Immunoregulatory effects of the herba Epimediia glycoside icariin.
In vitro study of icariin, a Chinese herbal extract, on human immune responses. Icariin induced proliferation of peripheral blood mononuclear cells, increased LAK and NK cell activity, and stimulated TNF-alpha production, suggesting potential for adoptive immunotherapy.